Nav: Home

New study identifies genetic variant that could help reduce need for liver transplants

April 02, 2019

A new study from The Westmead Institute for Medical Research has identified a genetic variant associated with liver fibrosis (scarring) in chronic hepatitis C patients. This finding is a step toward reducing the number of patients requiring liver transplants.

Researchers studied the role and mechanisms of a genetic variation in the MICA gene, a gene that is induced when cells are damaged.

The research team were able to show that, in 1,689 patients with chronic hepatitis C, the MICA gene variant rs2596542 is associated with the progression and severity of liver fibrosis.

They believe this occurs because rs2596542 triggers an immune response that increases the rate of liver fibrosis in patients with chronic hepatitis C infection.

First author of the study, Dr Rasha El Sharkawy said, "Understanding how and why liver fibrosis occurs is crucial for preventing health complications in those at risk.

"Chronic hepatitis C, liver fibrosis and hepatocellular carcinoma (or HCC - the most common form of primary liver cancer) are all serious conditions that are closely linked.

"Chronic hepatitis C is a major risk factor for liver cirrhosis (advanced liver fibrosis), and a leading cause of HCC in Australia. Liver scarring and chronic hepatitis C are both conditions that can lead to a liver transplant.

"The rate of fibrosis differs from person to person, so understanding the genetics behind liver fibrosis is critical for prevention.

"Now that we have identified a genetic variant associated with liver fibrosis in people with chronic hepatitis C, we can work towards targeting this variant to identify which patients are at greater risk of developing liver fibrosis, as well as creating better preventative measures and new treatments."

Currently, there are no approved treatments to reduce fibrosis in the liver. Liver transplantation is the only 'cure' for those with end-stage liver disease.

"Each year an estimated 339,000 people die globally from hepatitis C, mostly from cirrhosis and HCC," Dr El Sharkawy said.

"While some patients are eligible for a liver transplant to 'treat' complications, there are far more patients than there are donors, and not all patients are suitable for a transplant.

"Preventing the progression of fibrosis could reduce the number of patients who require a liver transplant.

"By identifying which patients are at a greater risk of fibrosis, we can potentially prevent complications of fibrosis before they occur.

"We can now also investigate the risk variant as a potential target for future treatments, reducing the overall number of patients living with liver complications."

The research paper was published in Scientific Reports:
The research was led by Professor Jacob George and Associate Professor Mohammed Eslam.

Dr Rasha El Sharkawy is affiliated with The Westmead Institute for Medical Research and the University of Sydney.

Professor Jacob George is affiliated with The Westmead Institute for Medical Research, the University of Sydney and Westmead Hospital.

Associate Professor Mohammed Eslam is associated with The Westmead Institute for Medical Research and the University of Sydney.

Westmead Institute for Medical Research

Related Hepatitis Articles:

Hepatitis C increasing among pregnant women
Hepatitis C infections among pregnant women nearly doubled from 2009-2014, likely a consequence of the country's increasing opioid epidemic that is disproportionately affecting rural areas of states including Tennessee and West Virginia.
WHO's Global Hepatitis Report sets baseline to eliminate viral hepatitis by 2030
The World Hepatitis Alliance today welcomes the publication of the first-ever Global Hepatitis Report by the World Health Organization (WHO), which includes new data on the prevalence and global burden of viral hepatitis.
Elimination of viral hepatitis by 2030: What's needed and how do we get there?
This first European Action Plan provides an important driver to aid countries in their fight against viral hepatitis, to which ECDC had the opportunity to contribute directly.
Discovery of new Hepatitis C virus mechanism
Researchers at Osaka University, Japan uncovered the mechanisms that suppress the propagation of the hepatitis C virus with the potential of improving pathological liver conditions.
Is Europe ready to eliminate viral hepatitis?
Currently, Europe records around 57,000 newly diagnosed acute and chronic cases of hepatitis B and C each year.
Why baby boomers need a hepatitis C screening
Hepatitis C affects a disproportionate amount of older Americans, born between 1945 and 1965.
Counterattack of the hepatitis B virus
The hepatitis B virus (HBV) infects liver cells. Drugs are available to treat HBV, but they rarely cure the infection, and so the virus typically returns after the treatment ends.
Hepatitis C tied to increased risk of Parkinson's
The hepatitis C virus may be associated with an increased risk of developing Parkinson's disease, according to a study published in the Dec.
The hepatitis A virus is of animal origin
The hepatitis A virus can trigger acute liver inflammation which generally has a mild course in small children but which can become dangerous in adults.
Modeling the helicase to understand hepatitis C
NS3 is an enzyme specific to the hepatitis C virus.

Related Hepatitis Reading:

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Digital Manipulation
Technology has reshaped our lives in amazing ways. But at what cost? This hour, TED speakers reveal how what we see, read, believe — even how we vote — can be manipulated by the technology we use. Guests include journalist Carole Cadwalladr, consumer advocate Finn Myrstad, writer and marketing professor Scott Galloway, behavioral designer Nir Eyal, and computer graphics researcher Doug Roble.
Now Playing: Science for the People

#529 Do You Really Want to Find Out Who's Your Daddy?
At least some of you by now have probably spit into a tube and mailed it off to find out who your closest relatives are, where you might be from, and what terrible diseases might await you. But what exactly did you find out? And what did you give away? In this live panel at Awesome Con we bring in science writer Tina Saey to talk about all her DNA testing, and bioethicist Debra Mathews, to determine whether Tina should have done it at all. Related links: What FamilyTreeDNA sharing genetic data with police means for you Crime solvers embraced...